Infertility Drugs Market Worth $5.6 Billion By 2030 | CAGR: 6.1%

Infertility Drugs Market Growth & Trends

The global infertility drugs market size is expected to reach USD 5.6 billion by 2030 expanding at a CAGR of 6.1% from 2023 to 2030 according to a new report by Grand View Research, Inc. The market seems to be saturated with fewer opportunities for new entrants. The companies including Merck & Co. Inc., Ferring B.V., and Organon group of companies holds majority of market share. Thus, the pharmaceutical companies are focusing on developing biosimilar of gonadotropins for market penetration. For instance, Qilu Pharmaceutical Co., Ltd. focuses on developing QL1012, a recombinant human follicle stimulating hormone which is under phase 3 clinical trial. Successful completion of of trial and subsequent launch is anticipated to drive market. 

Increasing initiatives undertaken by public and private organizations to support patients living with infertility are expected to positively contribute to infertility treatment market growth. For instance, in March 2022, the French government introduced new IVF law under which single women and same sex-couple avail treatment free of cost under the country’s national healthcare system. 

In addition, in November 2022, Saudi Arabia’s Health Insurance Council conducted studies with regard to the inclusion of medicines under medical insurance coverage. The successful completion of the study and inclusion of medication under insurance is anticipated to increase patient access to treatment, subsequently, increase demand for medicines over the forecast period. 

Rising awareness about disease and its available medicines among patients and physicians is anticipated to increase the target population for the market. For instance, in September 2021, Mubadala Health and United Eastern Medical Services (UEMedical) organized the ‘3^rd HealthPlus Middle East Fertility Conference with an aim to rise awareness about the advancements in the treatment of this conditions and its benefits among physicians and patients in Dubai. 

Moreover, there are several initiatives undertaken by the national government worldwide to tackle low fertility rate issues and promote childbirth which may increase the demand for drugs. For instance, in August 2022, the South Korean Government announced a provision for a monthly allowance of USD 740 per new child born in the family with an aim to tackle the low fertility rate in the country and encourage childbirth.

 Request a free sample copy or view report summary: Infertility Drugs Market Report

Infertility Drugs Market Report Highlights

• By drug class, the gonadotropin segment accounted for the largest share of the market in 2022 and is anticipated to witness fastest growth over the forecast period. This can be attributed to the availability of FDA-approved gonadotropins for infertility conditions in the market

• Based on end-user, the women segment dominated the infertility drugs market in 2022 owing to the rising incidence of the diseases such as PCOS, HPV associated vaginal cancer, uterine fibroids in women. As per the cohort studies published, in April 2022, approximately 1.5% of all French women aged 20 to 49 years were diagnosed with this condition annually.

• Hospiatal pharmacy segment dominated the infertility drugs market in 2022. This growth can be attributed to an increase in inpatient visits for the diagnosis and consulation of this condition worldwide

• North America dominated the global market in 2022 owing to factors such as high awareness among healthcare professionals about infertility conditions, ease of availability of drugs, and an increase in disease prevalence. 

Infertility Drugs Market Segmentation

Grand View Research has segmented the global infertility drugs market report based on, drug class, end-user, distribution channel, and region: 

Infertility Drugs Drug Class Outlook (Revenue, USD Million, 2018 - 2030)

• Gonadotropins

• Aromatase Inhibitors

• Selective Estrogen Receptor Modulators (SERMs)

• Dopamine Agonists

• Others

Infertility Drugs Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)

• Hospital Pharmacy

• Specialty & Retail Pharmacy

• Online Pharmacy

Infertility Drugs End-user Outlook (Revenue, USD Million, 2018 - 2030)

• Men

• Women

Infertility Drugs Regional Outlook (Revenue, USD Million; 2018 - 2030)

• North America

  • U.S.

  • Canada

• Europe

  • Germany

  • U.K.

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

  • Rest of Europe

• Asia Pacific

  • China

  • India

  • Japan

  • Australia

  • South Korea

  • Thailand

  • Rest of APAC

• Latin America

  • Brazil

  • Mexico

  • Argentina

  • Rest of LATAM

• Middle East & Africa

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

  • Rest of MEA

List of key players in Infertility Drugs Market include

• Merck & Co., Inc.

• Ferring B.V.

• Organon Group of Companies

• Abbott

• Novartis AG

• Bayer AG

• Pfizer Inc.

• Mankind Pharma

• Teva Pharmaceutical Industries LTD.

• Sanofi